A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
for Breast Cancer
Drug: Retifanlimab
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 18+
Code: NCT06959537·Phase 1·Recruiting·Listed May 2025